Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:FZR1-GNA11

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: FZR1-GNA11
	FusionPDB ID: 31970
	FusionGDB2.0 ID: 31970
		Hgene	Tgene
	Gene symbol	FZR1	GNA11
	Gene ID	51343	2767
	Gene name	fizzy and cell division cycle 20 related 1	G protein subunit alpha 11
	Synonyms	CDC20C\|CDH1\|FZR\|FZR2\|HCDH\|HCDH1	FBH\|FBH2\|FHH2\|GNA-11\|HHC2\|HYPOC2
	Cytomap	19p13.3	19p13.3
	Type of gene	protein-coding	protein-coding
	Description	fizzy-related protein homologCDC20 homolog 1CDC20-like 1bCDC20-like protein 1cdh1/Hct1 homologfizzy/cell division cycle 20 related 1	guanine nucleotide-binding protein subunit alpha-11g alpha-11guanine nucleotide binding protein (G protein), alpha 11 (Gq class)guanine nucleotide-binding protein G(y) subunit alpha
	Modification date	20200313	20200313
	UniProtAcc	Q9UM11 Main function of 5'-partner protein: FUNCTION: Substrate-specific adapter for the anaphase promoting complex/cyclosome (APC/C) E3 ubiquitin-protein ligase complex. Associates with the APC/C in late mitosis, in replacement of CDC20, and activates the APC/C during anaphase and telophase. The APC/C remains active in degrading substrates to ensure that positive regulators of the cell cycle do not accumulate prematurely. At the G1/S transition FZR1 is phosphorylated, leading to its dissociation from the APC/C. Following DNA damage, it is required for the G2 DNA damage checkpoint: its dephosphorylation and reassociation with the APC/C leads to the ubiquitination of PLK1, preventing entry into mitosis. Acts as an adapter for APC/C to target the DNA-end resection factor RBBP8/CtIP for ubiquitination and subsequent proteasomal degradation. Through the regulation of RBBP8/CtIP protein turnover, may play a role in DNA damage response, favoring DNA double-strand repair through error-prone non-homologous end joining (NHEJ) over error-free, RBBP8-mediated homologous recombination (HR) (PubMed:25349192). {ECO:0000269\|PubMed:18662541, ECO:0000269\|PubMed:21596315, ECO:0000269\|PubMed:25349192, ECO:0000269\|PubMed:9734353}.	P29992 Main function of 5'-partner protein: FUNCTION: Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Acts as an activator of phospholipase C. Transduces FFAR4 signaling in response to long-chain fatty acids (LCFAs). {ECO:0000269\|PubMed:27852822}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000313639, ENST00000395095, ENST00000441788,	ENST00000586180, ENST00000078429,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	11 X 9 X 10=990	5 X 7 X 5=175
	# samples	15	7
	** MAII score	log2(15/990*10)=-2.72246602447109 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(7/175*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: FZR1 [Title/Abstract] AND GNA11 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: FZR1 [Title/Abstract] AND GNA11 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	FZR1(3534511)-GNA11(3113327), # samples:1 FZR1(3534511)-GNA11(3113328), # samples:1
Anticipated loss of major functional domain due to fusion event.	FZR1-GNA11 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FZR1-GNA11 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FZR1-GNA11 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. FZR1-GNA11 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	FZR1	GO:0031145	anaphase-promoting complex-dependent catabolic process	18662541\|21596315
Hgene	FZR1	GO:0072425	signal transduction involved in G2 DNA damage checkpoint	18662541
Hgene	FZR1	GO:1904668	positive regulation of ubiquitin protein ligase activity	11459826

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:3534511/chr19:3113327)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across FZR1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across GNA11 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000441788	FZR1	chr19	3534511	+	ENST00000078429	GNA11	chr19	3113327	+	5260	1676	209	2434	741
ENST00000313639	FZR1	chr19	3534511	+	ENST00000078429	GNA11	chr19	3113327	+	4757	1173	0	1931	643
ENST00000395095	FZR1	chr19	3534511	+	ENST00000078429	GNA11	chr19	3113327	+	4940	1356	0	2114	704
ENST00000441788	FZR1	chr19	3534511	+	ENST00000078429	GNA11	chr19	3113328	+	5260	1676	209	2434	741
ENST00000313639	FZR1	chr19	3534511	+	ENST00000078429	GNA11	chr19	3113328	+	4757	1173	0	1931	643
ENST00000395095	FZR1	chr19	3534511	+	ENST00000078429	GNA11	chr19	3113328	+	4940	1356	0	2114	704

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000441788	ENST00000078429	FZR1	chr19	3534511	+	GNA11	chr19	3113327	+	0.002660934	0.99733907
ENST00000313639	ENST00000078429	FZR1	chr19	3534511	+	GNA11	chr19	3113327	+	0.002345019	0.9976549
ENST00000395095	ENST00000078429	FZR1	chr19	3534511	+	GNA11	chr19	3113327	+	0.002365488	0.99763453
ENST00000441788	ENST00000078429	FZR1	chr19	3534511	+	GNA11	chr19	3113328	+	0.002660934	0.99733907
ENST00000313639	ENST00000078429	FZR1	chr19	3534511	+	GNA11	chr19	3113328	+	0.002345019	0.9976549
ENST00000395095	ENST00000078429	FZR1	chr19	3534511	+	GNA11	chr19	3113328	+	0.002365488	0.99763453

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FZR1-GNA11

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
FZR1	chr19	3534511	GNA11	chr19	3113327	1173	391	RFWNVFSKTRSTKANALLIREVDVEK
FZR1	chr19	3534511	GNA11	chr19	3113327	1356	452	TGHSYRVLYLVKWANALLIREVDVEK
FZR1	chr19	3534511	GNA11	chr19	3113327	1676	489	RFWNVFSKTRSTKANALLIREVDVEK
FZR1	chr19	3534511	GNA11	chr19	3113328	1173	391	RFWNVFSKTRSTKANALLIREVDVEK
FZR1	chr19	3534511	GNA11	chr19	3113328	1356	452	TGHSYRVLYLVKWANALLIREVDVEK
FZR1	chr19	3534511	GNA11	chr19	3113328	1676	489	RFWNVFSKTRSTKANALLIREVDVEK

Top

Potential FusionNeoAntigen Information of FZR1-GNA11 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

FZR1-GNA11_3534511_3113327.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:24	TRSTKANAL	0.9967	0.5079	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B27:07	TRSTKANAL	0.9962	0.6576	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:01	TRSTKANAL	0.9944	0.8574	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:06	TRSTKANAL	0.9931	0.7918	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-A30:08	KTRSTKANA	0.9926	0.7241	7	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B14:02	TRSTKANAL	0.9921	0.807	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B14:01	TRSTKANAL	0.9921	0.807	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:16	STKANALLI	0.9917	0.6282	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:22	YLVKWANAL	0.987	0.7131	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-A30:08	STKANALLI	0.9864	0.6226	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:17	RSTKANALL	0.9828	0.9368	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:30	YLVKWANAL	0.9819	0.6562	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:24	YLVKWANAL	0.9819	0.6562	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:67	YLVKWANAL	0.9819	0.6562	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:60	YLVKWANAL	0.9811	0.6605	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:11	YLVKWANAL	0.9804	0.6845	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:16	RSTKANALL	0.9785	0.8723	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B38:02	TRSTKANAL	0.9767	0.9603	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:21	YLVKWANAL	0.9744	0.7515	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B38:01	TRSTKANAL	0.9728	0.9586	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:27	YLVKWANAL	0.9703	0.706	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:13	YLVKWANAL	0.9595	0.7924	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:04	YLVKWANAL	0.9588	0.8157	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:16	YLVKWANAL	0.9506	0.6277	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:17	YLVKWANAL	0.946	0.8022	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:35	YLVKWANAL	0.9153	0.6914	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B57:03	RSTKANALL	0.9051	0.9884	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:29	YLVKWANAL	0.8954	0.6573	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A31:02	KWANALLIR	0.8912	0.5027	11	20
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:10	TRSTKANAL	0.8824	0.5599	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:20	YLVKWANAL	0.873	0.6585	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:19	YLVKWANAL	0.8604	0.6556	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:38	YLVKWANAL	0.8546	0.8192	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-B46:01	YLVKWANAL	0.6209	0.6034	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:18	TRSTKANAL	0.5635	0.7509	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:37	TRSTKANAL	0.4952	0.5678	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-B52:01	VKWANALLI	0.0201	0.9777	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-A30:08	KTRSTKANAL	0.9827	0.7792	7	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C15:06	STKANALLI	0.9968	0.8712	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C15:06	RSTKANALL	0.9963	0.9444	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:09	TRSTKANAL	0.9954	0.7311	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:12	TRSTKANAL	0.9936	0.8638	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:95	TRSTKANAL	0.9889	0.7357	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:02	YLVKWANAL	0.9874	0.5829	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:05	TRSTKANAL	0.9844	0.9621	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:05	YLVKWANAL	0.9828	0.6716	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:01	YLVKWANAL	0.9819	0.6562	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:05	TRSTKANAL	0.9756	0.8437	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:13	TRSTKANAL	0.975	0.9607	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:27	TRSTKANAL	0.9735	0.96	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:29	TRSTKANAL	0.9706	0.9429	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-C03:19	YLVKWANAL	0.8641	0.996	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B73:01	TRSTKANAL	0.8577	0.6891	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:46	TRSTKANAL	0.8479	0.9208	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:19	TRSTKANAL	0.7934	0.7965	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:80	TRSTKANAL	0.7905	0.9633	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:67	TRSTKANAL	0.7905	0.9633	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:10	TRSTKANAL	0.788	0.962	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B14:03	TRSTKANAL	0.5735	0.8161	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C12:16	TRSTKANAL	0.0251	0.9679	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:12	TRSTKANALL	0.983	0.8588	8	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C15:02	STKANALLI	0.9979	0.8147	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C15:05	STKANALLI	0.997	0.8379	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C15:02	RSTKANALL	0.9968	0.8975	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C15:05	RSTKANALL	0.9966	0.9343	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B27:06	TRSTKANAL	0.9963	0.7396	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B27:09	TRSTKANAL	0.9956	0.8302	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-A30:01	KTRSTKANA	0.9931	0.8573	7	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:31	TRSTKANAL	0.9929	0.8584	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:01	TRSTKANAL	0.9891	0.732	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-A30:01	STKANALLI	0.9885	0.8048	10	19
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:03	YLVKWANAL	0.9877	0.7491	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:06	YLVKWANAL	0.9744	0.7515	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-A02:14	YLVKWANAL	0.9737	0.7243	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B38:05	TRSTKANAL	0.9728	0.9586	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C06:08	TRSTKANAL	0.9637	0.9903	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-C03:03	YLVKWANAL	0.9592	0.994	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-C03:04	YLVKWANAL	0.9592	0.994	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:17	TRSTKANAL	0.9348	0.9724	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-C03:67	YLVKWANAL	0.9227	0.9899	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-B15:73	YLVKWANAL	0.8733	0.9787	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B57:02	RSTKANALL	0.8704	0.9039	9	18
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:04	TRSTKANAL	0.8514	0.957	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-B15:30	YLVKWANAL	0.8213	0.9702	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:02	TRSTKANAL	0.7905	0.9633	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C07:22	TRSTKANAL	0.7539	0.7099	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B15:09	TRSTKANAL	0.7384	0.848	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-B39:11	TRSTKANAL	0.6923	0.7445	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C03:67	TRSTKANAL	0.3497	0.983	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C06:06	TRSTKANAL	0.3127	0.9927	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	HLA-B40:21	YLVKWANAL	0.0558	0.516	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C06:02	TRSTKANAL	0.0362	0.9943	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-C06:17	TRSTKANAL	0.0362	0.9943	8	17
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	HLA-A30:01	KTRSTKANAL	0.9848	0.9052	7	17

Top

Potential FusionNeoAntigen Information of FZR1-GNA11 in HLA II

FZR1-GNA11_3534511_3113327.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0701	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0703	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0705	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0707	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0708	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0709	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0712	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0713	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0714	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0715	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0716	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0717	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1173	DRB1-0719	FWNVFSKTRSTKANA	1	16
FZR1-GNA11	chr19	3534511	chr19	3113327	1356	DRB1-1537	VLYLVKWANALLIRE	6	21

Top

Fusion breakpoint peptide structures of FZR1-GNA11

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8715	SKTRSTKANALLIR	FZR1	GNA11	chr19	3534511	chr19	3113327	1173

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10114	VLYLVKWANALLIR	FZR1	GNA11	chr19	3534511	chr19	3113327	1356

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FZR1-GNA11

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	8715	SKTRSTKANALLIR	-7.15543	-7.26883
HLA-B14:02	3BVN	8715	SKTRSTKANALLIR	-4.77435	-5.80965
HLA-B52:01	3W39	8715	SKTRSTKANALLIR	-6.80875	-6.92215
HLA-B52:01	3W39	8715	SKTRSTKANALLIR	-4.20386	-5.23916
HLA-A11:01	4UQ2	8715	SKTRSTKANALLIR	-7.5194	-8.5547
HLA-A11:01	4UQ2	8715	SKTRSTKANALLIR	-6.9601	-7.0735
HLA-A24:02	5HGA	8715	SKTRSTKANALLIR	-7.52403	-7.63743
HLA-A24:02	5HGA	8715	SKTRSTKANALLIR	-5.82433	-6.85963
HLA-B27:05	6PYJ	8715	SKTRSTKANALLIR	-3.28285	-4.31815
HLA-B44:05	3DX8	8715	SKTRSTKANALLIR	-5.91172	-6.94702
HLA-B44:05	3DX8	8715	SKTRSTKANALLIR	-4.24346	-4.35686
HLA-B14:02	3BVN	10114	VLYLVKWANALLIR	-7.02924	-7.14264
HLA-B14:02	3BVN	10114	VLYLVKWANALLIR	-3.38077	-4.41607
HLA-B52:01	3W39	10114	VLYLVKWANALLIR	-6.41355	-6.52695
HLA-B52:01	3W39	10114	VLYLVKWANALLIR	-4.44188	-5.47718
HLA-A24:02	5HGA	10114	VLYLVKWANALLIR	-7.76595	-8.80125
HLA-A24:02	5HGA	10114	VLYLVKWANALLIR	-7.30892	-7.42232
HLA-B44:05	3DX8	10114	VLYLVKWANALLIR	-5.65486	-5.76826
HLA-B44:05	3DX8	10114	VLYLVKWANALLIR	-2.95775	-3.99305
HLA-B35:01	1A1N	10114	VLYLVKWANALLIR	-9.17605	-10.2113
HLA-B35:01	1A1N	10114	VLYLVKWANALLIR	-7.23657	-7.34997

Top

Vaccine Design for the FusionNeoAntigens of FZR1-GNA11

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
FZR1-GNA11	chr19	3534511	chr19	3113327	10	19	STKANALLI	TCGACAAAGGCCAATGCGCTCCTGATC
FZR1-GNA11	chr19	3534511	chr19	3113327	10	19	VKWANALLI	GTAAAGTGGGCCAATGCGCTCCTGATC
FZR1-GNA11	chr19	3534511	chr19	3113327	11	20	KWANALLIR	AAGTGGGCCAATGCGCTCCTGATCCGG
FZR1-GNA11	chr19	3534511	chr19	3113327	7	16	KTRSTKANA	AAAACCCGTTCGACAAAGGCCAATGCG
FZR1-GNA11	chr19	3534511	chr19	3113327	7	17	KTRSTKANAL	AAAACCCGTTCGACAAAGGCCAATGCGCTC
FZR1-GNA11	chr19	3534511	chr19	3113327	8	17	TRSTKANAL	ACCCGTTCGACAAAGGCCAATGCGCTC
FZR1-GNA11	chr19	3534511	chr19	3113327	8	17	YLVKWANAL	TACCTGGTAAAGTGGGCCAATGCGCTC
FZR1-GNA11	chr19	3534511	chr19	3113327	8	18	TRSTKANALL	ACCCGTTCGACAAAGGCCAATGCGCTCCTG
FZR1-GNA11	chr19	3534511	chr19	3113327	9	18	RSTKANALL	CGTTCGACAAAGGCCAATGCGCTCCTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
FZR1-GNA11	chr19	3534511	chr19	3113327	1	16	FWNVFSKTRSTKANA	TTCTGGAACGTCTTTAGCAAAACCCGTTCGACAAAGGCCAATGCG
FZR1-GNA11	chr19	3534511	chr19	3113327	6	21	VLYLVKWANALLIRE	GTGCTGTACCTGGTAAAGTGGGCCAATGCGCTCCTGATCCGGGAG

Top

Information of the samples that have these potential fusion neoantigens of FZR1-GNA11

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
UCEC	FZR1-GNA11	chr19	3534511	ENST00000313639	chr19	3113327	ENST00000078429	TCGA-FI-A2D2
UCEC	FZR1-GNA11	chr19	3534511	ENST00000395095	chr19	3113327	ENST00000078429	TCGA-FI-A2D2

Top

Potential target of CAR-T therapy development for FZR1-GNA11

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to FZR1-GNA11

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to FZR1-GNA11

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)